Home > Healthcare > Medical Devices > Diagnostic Devices > Pancreatic Cancer Diagnostic Market

Pancreatic Cancer Diagnostic Market Share

Report ID: GMI9826
Published Date: Jun 2024
Report Format: PDF

Download Free Sample

Pancreatic Cancer Diagnostic Market Share

The pancreatic cancer diagnostic sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Pancreatic Cancer Diagnostic Market Companies

Some of the eminent market participants operating in the pancreatic cancer diagnostic industry include:

Abbott Laboratories
Agilent Technologies, Inc.
ASURAGEN, INC.
Becton, Dickinson and Company
BioMarker Strategies
Canon Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
GE HealthCare Technologies Inc.
Hitachi, Ltd.
Illumina, Inc.
Koninklijke Philips N.V.
Myriad Genetics, Inc.
Prestige Biopharma Limited (PBP)
QIAGEN N.V.
Siemens Healthineers AG
Sysmex Corporation
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pancreatic cancer diagnostic industry size was worth USD 6 billion in 2023 and will expand at an 9.1% CAGR between 2024 and 2032 owing to rising incidence of pancreatic cancer worldwide and ongoing R&D efforts to improve diagnostic methods.

The imaging test segment in the pancreatic cancer diagnostic industry registered USD 2.2 billion in 2023, propelled by the critical role imaging plays in early and accurate detection of pancreatic cancer coupled with non-invasive nature and increasing accessibility of these imaging modalities.

North America pancreatic cancer diagnostic industry will record USD 4.7 billion by 2032 due to the region's advanced healthcare infrastructure, widespread adoption of advanced diagnostic technologies and government initiatives promoting cancer awareness.

Key players operating in the pancreatic cancer diagnostic industry are Abbott Laboratories, Agilent Technologies, Inc., ASURAGEN, INC., Becton, Dickinson and Company, Canon Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hitachi, Ltd., Illumina, Inc., Myriad Genetics, Inc., and Prestige Biopharma Limited (PBP), among others.